| アブストラクト | PURPOSE: To describe trends in the pharmacological treatment of BPH in the United Kingdom (UK) from 1998 to 2016. METHODS: We created a cohort of men with a diagnosis of BPH between 1998 and 2016 using the Clinical Practice Research Datalink. Using Poisson regression, we estimated annual prescription rates of 5alphaRIs, alpha-blockers, and combination therapy (5alphaRIs + alpha-blockers). Adherence was defined by a proportion of days covered > 80%. RESULTS: Our cohort included 192,640 men with BPH who generated 1,176,264 person-years (PYs) of follow-up. The mean age was 68.0 (standard deviation: 10.7) years. The prescription rate of all BPH medications during the study period was 347.6 per 100 PYs (95% CI 347.2-347.9). alpha-Blockers had the highest prescription rate (222.9 per 100 PYs, 95% CI 222.7-223.2); prescription rates of 5alphaRIs and combination therapy were 69.1 per 100 PYs (95% CI 69.0-69.3) and 55.5 per 100 PYs (95% CI 55.4-55.7), respectively. The prescription rate for combination therapy was 19 times greater in 2013-2016 than in 1998-2000 (rate ratio: 19.2, 95% CI 18.6-19.7), while the prescription rates for 5alphaRIs and alpha-blockers each doubled during this period (rate ratio: 1.86, 95% CI 1.84-1.88 and rate ratio: 2.02, 95% CI 2.01-2.04, respectively). The proportion of patients who were adherent at 1 year to 5alphaRIs (32.3%), alpha-blockers (44.0%), and combination therapy (45.6%) was low. CONCLUSION: The prescription rate of BPH medications increased substantially between 1998 and 2016 in the UK, with the greatest relative increase observed with combination therapy. Adherence to BPH medications was low in this population-based study. |
|---|
| 投稿者 | Ayele, Henok Tadesse; Reynier, Pauline; Azoulay, Laurent; Platt, Robert W; Cabaussel, Josselin; Benayoun, Serge; Filion, Kristian B |
|---|
| 組織名 | Department of Epidemiology, Biostatistics, Occupational Health, McGill;University, Montreal, Canada.;Center for Clinical Epidemiology, Lady Davis Institute, Jewish General Hospital,;Montreal, Canada.;Gerald Bronfman Department of Oncology, McGill University, Montreal, Canada.;Department of Pediatrics, McGill University, Montreal, Canada.;Department of Surgery, Urology Unit, Hopital Maisonneuve-Rosemont, Montreal,;Canada.;University, Montreal, Canada. kristian.filion@mcgill.ca.;Montreal, Canada. kristian.filion@mcgill.ca.;Departments of Medicine and of Epidemiology, Biostatistics, and Occupational;Health, McGill University, 3755 Cote Ste Catherine, Suite H410.1, Montreal, QC,;H3T 1E2, Canada. kristian.filion@mcgill.ca. |
|---|
